(SYBX) Synlogic, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SYBX) Synlogic, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Synlogic, Inc. 4P's Marketing Mix Analysis explains the company’s Product, Price, Place, and Promotion strategy and shows how those elements support positioning and sales; this page includes a real preview/sample of the report so you can review style and content before buying—purchase the full version to get the complete, ready-to-use analysis.
Product
SYNB1618 Phase II PKU
SYNB1618 is Synlogic, Inc.'s oral, non-systemically absorbed synthetic biotic in Phase II for phenylketonuria (PKU), a rare metabolic disorder affecting about 1 in 23,000 to 1 in 31,500 newborns. The product fits a chronic-use model because PKU needs lifelong management, often with strict low-phenylalanine diet and ongoing monitoring. Its 4P edge is clear: rare-disease focus, oral dosing, and a treatment gap with durable demand.
SYNB1934 Phase II PKU
SYNB1934 is an oral, non-systemic synthetic biotic in Phase II for phenylketonuria, a rare disease affecting about 1 in 10,000 to 15,000 births. It gives Synlogic, Inc. a second clinical-stage program in the same high-value rare-disease market. That can deepen pipeline optionality and widen reach across the PKU treatment space.
SYNB1353 Homocystinuria
SYNB1353 is an oral, non-systemically absorbed candidate for homocystinuria, a rare disease affecting about 1 in 200,000 to 1 in 335,000 people. Its local gut action aims to lower toxic metabolites without broad body exposure, and it broadens Synlogic, Inc.’s metabolic disease pipeline beyond PKU. In 2026, rare-disease therapies still target small populations, so even modest uptake can matter.
SYNB8802 Phase I Enteric Hyperoxaluria
SYNB8802 is an oral, non-systemic live biotherapeutic in Phase I for enteric hyperoxaluria, a rare metabolic disease tied to kidney stone risk. For Synlogic, Inc., it widens the product portfolio beyond one rare indication and supports the 4P place strategy with a convenient take-at-home dose.
- Oral dosing improves patient access
- Non-systemic design limits exposure
- Phase I means early human proof
- Rare-disease fit supports niche pricing
SYNB1891 Phase I Solid Tumors and Lymphoma
SYNB1891 is Synlogic, Inc.’s intratumoral synthetic biotic candidate in Phase I for solid tumors and lymphoma, so it adds an oncology step beyond the company’s oral microbiome-focused work. Intratumoral delivery aims to act inside the tumor, which can support local immune activation with less whole-body exposure. Phase I means early safety and dose testing in humans.
- Intratumoral, not oral
- Phase I in solid tumors and lymphoma
- Adds oncology to the portfolio
- Early safety and dose study
Synlogic’s Orphan Biotics Pipeline Targets Rare Diseases and Cancer
Synlogic, Inc.’s product mix is built on oral, non-systemic synthetic biotics across rare diseases and oncology. The main value lies in low-burden dosing, local gut or tumor action, and niche orphan-drug demand.
PKU programs SYNB1618 and SYNB1934 target a market tied to lifelong diet control, while SYNB1353 and SYNB8802 broaden the pipeline into homocystinuria and enteric hyperoxaluria. SYNB1891 adds intratumoral oncology exposure, with all lead assets still in early-stage testing.
| Asset | Use | Stage |
|---|---|---|
| SYNB1618 | PKU | Phase II |
| SYNB1934 | PKU | Phase II |
| SYNB1353 | Homocystinuria | Phase II |
| SYNB8802 | Enteric hyperoxaluria | Phase I |
| SYNB1891 | Solid tumors, lymphoma | Phase I |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific breakdown of Synlogic, Inc.’s Product, Price, Place, and Promotion strategy with real-world context.
Editable Excel File
Distills Synlogic, Inc.’s 4Ps into a quick, decision-ready snapshot that saves time and simplifies marketing analysis.
Reference Sources
Lists primary, reputable sources used to validate Synlogic's market sizing, pricing, and competitive assumptions for fast, traceable decision support.
Place
Cambridge, Massachusetts HQ
Synlogic’s main office is in Cambridge, Massachusetts, anchoring corporate leadership, research planning, and partner outreach in one place. Cambridge, especially Kendall Square, sits in one of the strongest U.S. biotech clusters, with dense access to labs, investors, and talent. That location helps Synlogic move faster on collaborations and keeps it close to the science it needs.
United States Clinical Focus
Synlogic, Inc. keeps its place strategy centered on the United States, where clinical development runs through domestic study sites and FDA pathways. That U.S.-only access model fits a biotech with no reported product revenue in FY2025, so trial reach and regulatory speed matter more than physical distribution.
Investigator-Site Trial Supply
Synlogic’s products are investigational, so they do not move through retail channels; distribution runs through clinical trial supply chains instead. Access is limited to enrolled study participants and investigators at active sites, which keeps the reach narrow and tightly controlled. In 2025, that model still means zero consumer availability and site-level dispensing only, with supply aligned to protocol needs and patient counts.
Oral Patient Access Model
Synlogic, Inc.'s patient access model was built around oral dosing, with its main pipeline programs designed as swallowable therapies rather than infusions. That matters because oral use can avoid hospital infusion visits, cut site burden, and make enrollment easier for patients and trial sites. The pipeline centered on 2 oral lead assets in metabolic disease.
- Oral, not infusion-based
- Fits outpatient use
- Less site logistics
- Supports patient convenience
Specialist Oncology Centers
SYNB1891 is given intratumorally, so Synlogic, Inc. must focus on specialist oncology centers with trained teams, imaging support, and procedure rooms for tumor-directed dosing. That narrows access to a smaller set of sites that can safely place and monitor local cancer therapy, which can slow rollout but improves control.
For the 4P place strategy, the channel is not broad retail or standard hospital pharmacy; it is a tightly managed center network built for oncology procedures.
- Intratumoral dosing needs expert clinical teams
- Specialist centers support safe tumor access
- Distribution stays limited to equipped oncology sites
Synlogic’s Trial-Only Reach Keeps Distribution Tight in FY2025
Synlogic, Inc. keeps Place narrow: Cambridge, Massachusetts for leadership and U.S. trial sites for access. Its investigational drugs move through clinical supply chains, not retail, so distribution stays limited to enrolled patients and specialist investigators. In FY2025, that model matched zero product revenue and site-level dispensing only.
| Place element | FY2025 detail |
|---|---|
| HQ | Cambridge, Massachusetts |
| Channel | U.S. clinical sites |
| Access | Trial-only, no retail |
Full Version Awaits
Synlogic, Inc. Reference Sources
The preview shown here is the actual Synlogic, Inc. 4P's Marketing Mix Analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.
Promotion
Clinical Trial Disclosures
Synlogic promotes its pipeline through public clinical-trial disclosures, with Phase I and Phase II status at the center of the message. These updates show where each program sits in development and help patients, investigators, and investors track progress. The trial-stage focus is especially important because early clinical readouts often drive valuation moves in biotech.
Investor Relations Communications
Synlogic, Inc. used investor relations communications to explain pipeline progress, mainly through press releases and business updates. In a public-company setting, this mattered because it kept market awareness high even when operating results were still loss-making and milestone-driven rather than sales-driven.
Scientific and Medical Outreach
Clinical-stage biopharma promotion leans on peer-reviewed data, not broad ads. For Synlogic, disease-specific and mechanism-based messaging helps physicians and researchers see how live biotherapeutic candidates target the root cause, which matters when sales are still $0 and value must be proven in the clinic. That keeps outreach scientific, focused, and credibility-led.
Partnership Announcements
Synlogic’s partnership news with F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc., and Ginkgo Bioworks, Inc. gives the platform third-party validation. These collaborations expand reach beyond Synlogic’s own channels and help keep the company visible to investors and biotech partners. With 3 named partners, the promotion story leans on external credibility, not just internal messaging.
- 3 named strategic partners
- Third-party platform validation
- Broader market visibility
Rare-Disease Targeting
Synlogic, Inc. can keep promotion sharply targeted because PKU affects about 1 in 10,000 to 15,000 births, while homocystinuria is about 1 in 200,000 to 335,000 births. Enteric hyperoxaluria is also rare and tied to clear patient groups, so education can go straight to metabolic clinics, nephrologists, and patient groups.
That niche reach matters: with small, defined communities, one strong scientific message can drive awareness faster than broad media spend.
- PKU has a defined screening path
- Homocystinuria has tiny, reachable cohorts
- Enteric hyperoxaluria needs specialist education
- Promotion should center on disease literacy
Synlogic’s Rare-Disease Marketing: Small Audience, Strong Validation
Synlogic’s promotion was scientific and narrow: clinical-trial updates, investor releases, and partner news carried the message. In rare diseases, that fit the audience and kept attention on Phase I/II progress, not broad consumer reach.
Third-party validation from Roche and Ginkgo helped extend visibility. The key edge was disease-specific education for tiny, reachable cohorts.
| Item | Data |
|---|---|
| Named partners | 3 |
| PKU birth rate | 1 in 10,000 to 15,000 |
| Homocystinuria | 1 in 200,000 to 335,000 |
Price
No Commercial Price
Synlogic, Inc. is still a clinical-stage company, so it has no commercial product price to disclose. In FY2025, pricing could not be set publicly because no approved, marketed therapy was available. Until regulatory approval and launch, Synlogic’s 4P pricing element remains "no commercial price."
Investigational Access Only
Synlogic, Inc. is in an investigational-only price stage: its current assets are being tested in Phase I and Phase II trials, so patients access therapy through the study, not a retail sale. That means the sticker price today is effectively $0 for participants, with no commercial list price set. In this model, value is tied to trial availability, not a marketed product.
Partner-Funded Development
Synlogic, Inc. leans on partner-funded development, with Roche and Ginkgo helping finance research before sales begin. That lowers near-term pressure to set end-customer prices, since R&D cash can come from collaboration fees and milestones instead of product revenue. For a clinical-stage company with no commercial product sales, this model keeps pricing power off the critical path.
Future Specialty Pricing
Synlogic, Inc.'s pipeline is aimed at rare metabolic diseases and oncology, so any approved therapy would likely sit in specialty pricing bands rather than mass-market pricing. In rare disease, annual drug prices often land in the $200,000 to $500,000 range, while oncology products can price above $100,000 per treatment course, but final pricing would hinge on reimbursement, manufacturing cost, and proven clinical benefit.
- Rare disease pricing: often $200,000-$500,000 yearly
- Oncology pricing: often above $100,000 per course
- Reimbursement will shape net realized price
- Manufacturing cost and value drive final price
No Public Discount Terms
Synlogic, Inc. does not disclose public consumer pricing, discounts, or credit terms for its pipeline, and that fits a biopharma model rather than retail sales. Price stays undefined until a product is approved and commercialization starts, so there is no list price to benchmark today. In 2025, Synlogic remained a development-stage company, so pricing power is still tied to future clinical and regulatory milestones.
- No public price or discount terms
- No retail-style credit policy
- Price set only at commercialization
Synlogic FY2025 Price: Still Unset, With No Marketed Product
Synlogic, Inc.'s price is still unset in FY2025 because it had no approved, marketed product. That means no public list price, no discounts, and no retail terms; the current effective price to trial users is $0. Any future price would depend on approval, reimbursement, and value.
| Metric | FY2025 |
|---|---|
| Commercial list price | 0 |
| Marketed product | No |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.